Imbruvica
1 known investors
IMBRUVICA is a prescription cancer medication (available as capsules, tablets, and oral suspension) used to treat B-cell malignancies such as CLL/SLL and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease in adults and children. It is marketed by AbbVie, and the page provides patient dosing instructions, safety warnings, and side-effect information.
Investors · 1
In the news
Frequently asked questions
- What does Imbruvica do?
- IMBRUVICA is a prescription cancer medication (available as capsules, tablets, and oral suspension) used to treat B-cell malignancies such as CLL/SLL and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease in adults and children. It is marketed by AbbVie, and the page provides patient dosing instructions, safety warnings, and side-effect information.
- Who are Imbruvica's investors?
- Imbruvica's investors include Aisling Capital.